Indian government outlines policies on drug pricing to favor poorer patients, and increase clinical trials

The Indian government is looking to review the existing drug price control measures in order to make medicines more affordable in the country, and at increasing the number of clinical trials taking place in the country, reports The Pharma Letter’s India correspondent.

In a parallel move, the Health Ministry is also preparing a framework for public private partnership to tackle the menace of non-communicable diseases in the country. In a move that could potentially result in affordable Medicare and health security moving to a larger section of the population, the government is considering a raft of policy measures in favor of poor patients.

Talks are also on in government circles to abolish clinical trials on proven drugs that have been approved and marketed for at least two years in the European Union, USA, UK, Australia, Canada and Japan.